MAIA - MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
Story updates
12:21:11 PM UTC
SquawkNews
Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficienciesU.S. expansion is funded by a $2.3 million NIH grant to MAIA to support third-line treatment evaluationCHICAGO, Sept. 16, 2026 (GLOBE NEWSWIRE…
12:22:06 PM UTC
SquawkNews
MAIA Biotechnology dosed the first U.S. patient in its Phase 2 THIO-101 expansion evaluating ateganosine in third-line NSCLC, supported by a $2.3M NIH grant. The study follows FDA clearance of an amended IND and holds Fast Track designation.Material DetailsContext by AI AnalystThis is an operationa…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.